TriangleHEALTH PROFESSIONAL · SOURCE READING
Response Rates for Primary Refractory Hodgkin Lymphoma
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents
Salvage rates for patients with primary refractory Hodgkin lymphoma are poor even with autologous HSCT and radiation. However, some studies have reported that intensification of therapy followed by HSCT consolidation can achieve long-term survival.
Evidence (response to treatment of primary refractory Hodgkin lymphoma):
In one large series, the 5-year OS rate was 49% for patients with primary refractory Hodgkin lymphoma after receiving aggressive second-line therapy (high-dose chemoradiation therapy) and autologous HSCT.[63]
Source links and citations
In a Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) study, patients with primary refractory Hodgkin lymphoma (progressive disease on therapy or relapse within 3 months from the end of therapy) had 10-year event-free survival (EFS) and OS rates of 41% and 51%, respectively.[4]
Source links and citations
In a study of 53 adolescent patients (like those who participated in the GPOH study), EFS and OS rates were similar.[64] Chemosensitivity to standard-dose, second-line chemotherapy predicted better survival (OS rate, 66%), and tumors that remained refractory to chemotherapy did poorly (OS rate, 17%).[65]
Another group reported a PFS rate of 80% post-HSCT for chemosensitive patients, compared with 0% for those with chemoresistant disease.[40]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice